Compare Adaptive Biotechnologies Corp (ADPT) vs Lucid Group Inc (LCID) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Lucid Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Lucid Group Inc trades at $5.95 (market cap $2.34B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | LCID | |
|---|---|---|
Market Cap | $3.33B | $2.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $31.30 |
52-Week Low | $10.24 | $4.70 |
Enterprise Value | $3.19B | $4.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Lucid Group (LCID) trades at $5.995, down 1.4% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 deliveries of 3,093 vehicles, missing expectations, alongside a leadership overhaul. Financially, LCID shows severe losses with a net income margin of -239.81% in 2025 and negative cash flow from operations of -$2.93B, though revenue grew to $1.35B.
The outlook remains challenging due to persistent losses and high cash burn, but the consensus price target of $11.75 suggests potential upside if execution improves. Key risks include ongoing class-action lawsuits, competitive pressures in the EV market, and reliance on Saudi funding. Investors should weigh the high-risk profile against long-term growth prospects in electric vehicles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
